Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Non-Current Liabilities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Total Non-Current Liabilities for 11 consecutive years, with -$117000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 100.18% year-over-year to -$117000.0, compared with a TTM value of -$117000.0 through Sep 2025, down 100.18%, and an annual FY2024 reading of $17.3 million, up 113.17% over the prior year.
  • Total Non-Current Liabilities was -$117000.0 for Q3 2025 at Avalo Therapeutics, down from $11.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $219.1 million in Q1 2024 and bottomed at -$117000.0 in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $42.2 million, with a median of $36.5 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 564.01% in 2024, then crashed 100.18% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $54.8 million in 2021, then decreased by 22.36% to $42.6 million in 2022, then tumbled by 80.88% to $8.1 million in 2023, then skyrocketed by 113.17% to $17.3 million in 2024, then crashed by 100.67% to -$117000.0 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for AVTX at -$117000.0 in Q3 2025, $11.7 million in Q2 2025, and $15.6 million in Q1 2025.